
Your respiratory program, from molecule to approval
Our development team includes people who contributed to BEVESPI AEROSPHERE® and BREZTRI AEROSPHERE™, approved in the U.S., EU, China and Japan.
From study design through submission to approval

- Pre-clinical
- Phase 1
- Phase 2
- Phase 3
- Registration
- Approval
Our team has collectively contributed to more than 50 approved products or label expansions across the globe over the past 30 years.
1Design
Our specialists design an efficient clinical program to support regional or global registration, with customized trials built on scientifically sound methods and regulatory guidelines from protocol design onward.
Study design, protocol design, clinical program design
2Develop
We manage your trials, tap an extensive network of clinical trial sites, recruit patients with precision and keep trial data accurate and secure, with insights that support timely decisions.
Clinical trial management, site and patient recruitment, data management and analysis
3Deliver
We prepare comprehensive submissions for global health authorities and negotiate with them through to approval. Our team has led major sponsor inspections in the U.S., EU, China and Japan.
Regulatory submissions to FDA, EMA, PMDA, MHRA, Health Canada, TGA and NMPA
Run by the people who did it before
DevPro was founded by former Pearl Therapeutics and AstraZeneca executives. Together our team brings over a century of shared clinical development experience.

Colin Reisner, MD
Founder & CEO
Previously CEO of Pearl Therapeutics and SVP at AstraZeneca

Earl St. Rose
Founder & COO
Previously VP at Pearl Therapeutics and AstraZeneca

Pramila Monte
Founder & Chief Strategy and Clinical Development Officer
Over 21 years in clinical safety and health authority inspections

Catherine Pelc
Founder & Chief People and Business Operations Officer
Over 26 years in clinical operations

Kim Rossman
Founder & Chief Clinical Execution and Delivery Officer
Over 29 years in clinical trial execution
The respiratory conditions we work in
Our work is respiratory focused. Alongside our own albuterol inhaler, we partner with Uniquity Bio on Phase 2 asthma and COPD studies of its monoclonal antibody.
- 01COPD
- 02Asthma
- 03Idiopathic pulmonary fibrosis
- 04Progressive pulmonary fibrosis
- 05Cystic fibrosis
- 06Pulmonary hypertension
- 07Alpha-1 antitrypsin deficiency
7physicians at leading research institutes and medical schools in the U.S. and Europe
- Gary T. Ferguson, MDDirector, Pulmonary Research Institute of Southeast Michigan
- MeiLan K. Han, MD, MSDirector, Michigan Airways Program, University of Michigan Health System
- Fernando J. Martinez, MD, MSChief, Pulmonary and Critical Care Medicine, Weill Cornell Medical College
- Sydney Montesi, MDAssistant Professor of Medicine, Harvard Medical School
- Klaus F. Rabe, MDProfessor of Pulmonary Medicine, University of Kiel
- Lisa Saiman, MDProfessor of Pediatrics, Columbia University Medical Center
- David S. Wilkes, MDDean, University of Virginia School of Medicine
Ways to partner with us
1Your development company
We partner as a stand-alone development company, running full development activities from concept through regulatory approvals.
2Co-development
If you are a pharma company or a venture capital investor, we can jointly identify and develop new molecular entities with you.
Partnering with our experienced team on our proven clinical development platform results in de-risked assets, accelerated timelines, lower costs and an increased likelihood of positive outcomes.
Discuss your programDevelopment pipeline
We develop cutting-edge products that address high unmet medical needs. Our current clinical trials are in Phase 1 and Phase 2.
Product names confidential.
News
Honeywell technology to power our low-emission inhaler
A long-term supply agreement for Honeywell Solstice® Air, a propellant that can cut metered dose inhaler greenhouse gas emissions by up to 99.9% versus current propellants.
DevPro partners with Uniquity Bio on Phase 2 asthma and COPD studies
Uniquity Bio, a Blackstone Life Sciences portfolio company, is advancing solrikitug, a monoclonal antibody targeting TSLP, into Phase 2 studies in COPD and asthma.
DevPro and Bespak complete early feasibility studies for DP007
DP007 is an albuterol inhaler with a near-zero global warming potential propellant. We are inviting expressions of interest from investors and pharmaceutical organizations in the next phase.
Discuss your program
Tell us about your molecule, your indication and where it is in development.